Efficacy of tacrolimus as rescue therapy for chronic rejection in orthotopic liver transplantation: A report of the U.S. multicenter liver study group

Transplantation

Volumn 64, Issue 2, 1997, Pages 258-263

  Sher, Linda S ^a,s   Cosenza, Carlos A ^a   Michel, Jacques ^a   Makowka, Leonard ^a   Miller, Charles M ^e   Schwartz, Myron E ^e   Busuttil, Ronald ^b   Mcdiarmid, Sue ^b   Burdick, James F ^f   Klein, Andrew S ^f   Esquivel, Carlos ^c   Klintmalm, Goran ^g   Levy, Marlon ^g   Roberts, John P ^d   Lake, John R ^d   Kalayoglu, Munci ^h   D'Alessandro, Anthony M ^h   Gordon, Robert D ⁱ   Stieber, Andrei C ⁱ   Shaw Jr , Byers W ^j   Thistlethwaite, J Richard ^k   Whittington, Peter ^k   Wiesner, Russell H ^l   Porayko, Michael ^l   Bynon, J Steve ^m   Eckhoff, Devin E ^m   Freeman, Richard B ⁿ   Rohrer, Richard J ⁿ   Lewis, W David ^o   Marsh, J Wallis ^q   Peters, Marion ^r   Powelson, John ^p   Cosimi, A Benedict ^s   more..

^a ST VINCENT MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MOUNT SINAI MEDICAL CENTER   (United States)

^f DEPARTMENT OF PATHOLOGY   (United States)

^g BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^h University of Wisconsin Health   (United States)

ⁱ EMORY UNIVERSITY HOSPITAL   (United States)

^j UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^k UNIVERSITY OF CHICAGO   (United States)

^l MAYO CLINIC   (United States)

^m UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁿ TUFTS MEDICAL CENTER   (United States)

^o BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^p MASSACHUSETTS GENERAL HOSPITAL   (United States)

^q UNIVERSITY OF PITTSBURGH   (United States)

^r WASHINGTON UNIVERSITY   (United States)

^s Institute Plaza ^*  (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ALLOGRAFT; ARTICLE; BILIRUBIN BLOOD LEVEL; CHILD; CHRONIC DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT FAILURE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; CHILD; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; TACROLIMUS; TREATMENT OUTCOME;

EID: 0030763028     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199707270-00014     Document Type: Article

References (19)

1. Lowes JR, Hubscher SG, Neuberger JM. Chronic rejection of the liver allograft. Gastroenterol Clin North Am 1993; 22: 401.
2. Demetris AJ, Fung JJ, Todo S, et al. Conversion of liver allograft recipients from cyclosporine to FK 506 immunosuppressive therapy: a clinicopathologic study of 96 patients. Transplantation 1992; 53: 1056.
3. U.S. Multicenter FK 506 Liver Study Group. Use of Prograf (FK506) as rescue therapy for refractory rejection after liver transplantation. Transplant Proc 1993; 25: 679.
4. The U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 1110.
5. Vierling JM, Fennell RH. Histopathology of early and late human hepatic allograft rejection, evidence of progress destruction of interlobular bile ducts. Hepatology 1985; 5: 1076.
6. Ludwig J, Wiesner RH, Batts KP, et al. The acute vanishing bile duct syndrome (acute irreversible rejection) after orthotopic liver transplantation. Hepatology 1987; 7: 476.
7. Wiesner RH, Ludwig J, van Hoek B, Krom RAF Current concepts in cell-mediated hepatic allograft rejection leading to ductopenia and liver failure. Hepatology 1991; 14: 721.
8. Pirsch JD, Kalayoglu M, Hafez GR, et al. Evidence that the vanishing bile duct syndrome is vanishing. Transplantation 1990; 49: 1015.
9. O'Grady JG, Alexander GJM, Sutherland S, et al. Cytomegalovirus infection and donor/recipient HLA antigens: interdependent co-factors in pathogenesis of vanishing bile duct syndrome after liver transplantation. Lancet 1988; 2: 302.
10. Freese DK, Snover DC, Sharp HL, et al. Chronic rejection after liver transplantation: a study of clinical, histopathological and immunological features. Hepatology 1991; 13: 882.
11. van Hoek B, Wiesner RH, Krom RAF, et al. Severe ductopenic rejection following liver transplantation: incidence, time of on-set, risk factors, treatment and outcome. Semin Liver Dis 1992; 12: 41.
12. Hubscher SG, Buckels JAC, Elias E, et al. Vanishing bile-duct syndrome following liver transplantation: is it reversible? Transplantation 1991; 51: 1004.
13. Starzl TE, Todo S, Fung JJ, et al. FK506 for human liver, kidney and pancreas transplantation. Lancet 1989; 2: 1000.
14. The European FK506 Multicentre Liver Study Group Reduced incidence of acute, refractory acute and chronic rejection after liver transplantation with FK506-based immunosuppression. transplant Proc 1994; 26: 3260.
15. Millis JM, Woodle ES, Piper JB, et al. Tacrolimus for primary treatment of steroid-resistant hepatic allograft rejection. Transplantation 1996; 61; 1365.
16. Platz K-P, Mueller AR, Zytowski M, et al. OKT3 vs. FK 506 rescue management of acute steroid-resistant and chrome rejection. transplant Proc 1995; 27: 1111.
17. Sher LS, Cosenza CA, Petrovic LM, et al. Tacrolimus (FK506) for rescue therapy of chronic rejection following orthotopic liver transplantation. Transplant Proc 1996; 28: 1011.
18. Jost U, Winkler M, Ringe B, et al. FK 506 treatment of intractable rejection after liver transplantation. Transplant Proc 1993; 25: 2686.
19. Demetris AJ, Seaberg EC, Batts KP, et al. Reliability and predictive value of the National Institute of Diabetes and Digestive and Kidney Diseases Liver transplantation database nomenclature and grading system for cellular rejection of liver allografts. Hepatology 1995; 21: 408.